RSCF($.081): clearly not a value stock, but looks like an attractive bet on the future. The freezer line appears to be less than a year old. This is from the 6/4/20 PR:
In 2019 new market opportunities were sought in the biopharmaceutical and natural products extraction markets. The result was an improved blast freezer design with first in class specifications for the biopharmaceutical market and a solvent chiller for natural products extraction. Both products are based on patented liquid nitrogen cryogenic cooling technology and are product leaders in their respective capabilities. The chiller and the blast freezer were introduced to the market in late 2019 and the market responded in a very favourable manner.
The company's Q2 results were timely-filed at otcmarkets.com on 8/12/20.
Market Data 
Markets 
AI
